Syn­er­gy CEO pass­es torch to CCO Troy Hamil­ton; Pres­i­dent Steven Kaf­ka re­signs from Foun­da­tion; Ab­b­Vie vet John Leonard to helm In­tel­lia

Troy Hamil­ton

→ Mark­ing a new phase for the biotech, Syn­er­gy Phar­ma­ceu­ti­cals $SYGP an­nounced that co-founder and Tru­lance co-in­ven­tor Gary Ja­cob is pass­ing the CEO ba­ton to Troy Hamil­ton. Join­ing Syn­er­gy in 2015, Hamil­ton was chief com­mer­cial of­fi­cer and EVP, steer­ing the launch and com­mer­cial­iza­tion of Tru­lance. The chron­ic id­io­path­ic con­sti­pa­tion drug is right up Hamil­ton’s al­ley, as he man­aged the gas­troin­testi­nal unit at Shire for nine years af­ter spend­ing much of his ca­reer at Janssen and Mc­Neil Spe­cial­ty Prod­ucts. “One of my ini­tial ar­eas of fo­cus will be to work with our CFO, Gary Gemignani, and the Syn­er­gy man­age­ment team to con­tin­ue to re­fine our busi­ness plan and fo­cus on achiev­ing cost ef­fi­cien­cies through­out the com­pa­ny while pri­or­i­tiz­ing in­vest­ments that will dri­ve sig­nif­i­cant Tru­lance growth,” Hamil­ton said in the state­ment. He al­so made sure to thank Ja­cob, who will con­tin­ue his in­volve­ment with the com­pa­ny as ex­ec­u­tive chair­man of the board.

Steven Kaf­ka

→ Pres­i­dent and COO Steven Kaf­ka has in­formed Foun­da­tion Med­i­cine $FMI of his in­ten­tion to re­sign next Feb­ru­ary, trig­ger­ing a lead­er­ship reshuf­fle that adds the pres­i­dent ti­tle to CEO Troy Cox and COO role to SVP of in­ter­na­tion­al mar­kets Kon­stan­tin Fiedler. Kaf­ka’s tenure at Foun­da­tion last­ed al­most five years, no­tice­ably longer than his stints at oth­er biotechs in­clud­ing Mil­len­ni­um Phar­ma­ceu­ti­cals and Aileron Ther­a­peu­tics. Cox and Fiedler are both rel­a­tive­ly new to the biotech, but each had spent time at some big name com­pa­nies be­fore land­ing here.

→ Cam­bridge, MA-based start­up Dis­arm Ther­a­peu­tics has lured Pe­ter Keller to join as chief busi­ness of­fi­cer af­ter sev­en years at Se­lec­ta Bio­sciences. Keller hasn’t al­ways worked in biotech — he was a man­age­ment con­sul­tant for a decade — but while in the in­dus­try, he has been in­volved in an ac­qui­si­tion, a big IPO and a bil­lion-dol­lar deal. While we haven’t heard much about where Dis­arm’s ax­on­al de­gen­er­a­tion-pre­vent­ing tech is head­ed, we now know Keller will be shap­ing part of it.

Joe Jimenez

→ As Joe Jimenez con­tin­ues to search for his next big break af­ter No­var­tis (ide­al­ly in Sil­i­con Val­ley), he will spend some time in Cincin­nati as a mem­ber of Proc­ter & Gam­ble’s board of di­rec­tors. Con­sumer busi­ness is fa­mil­iar turf for Jimenez, who worked top jobs at Heinz be­fore tak­ing the reins of the Swiss phar­ma gi­ant.

→ In a clear sig­nal that CRISPR/Cas9 play­er In­tel­lia Ther­a­peu­tics is piv­ot­ing to a Phase I, John Leonard, found­ing chief med­ical of­fi­cer, is be­ing kicked up to the CEO’s of­fice. Hav­ing led the biotech $NT­LA through a quick and suc­cess­ful IPO in 2016, At­las part­ner Nes­san Berming­ham will re­turn to biotech ven­ture cap­i­tal. The R&D trek will like­ly be long, with ri­vals Ed­i­tas and CRISPR Ther­a­peu­tics — who are still fight­ing over the IP — de­ter­mined to have a slice of the mar­ket. The board is putting its faith in Leonard, the for­mer top sci­en­tist at Ab­b­Vie who worked on HIV and HCV while tak­ing a lead role on Hu­mi­ra dur­ing his 22-year tenure.

Gen­zyme vet Marc Beck­er will be Con­cert Phar­ma’s new CFO, af­ter a brief stint at CRISPR Ther­a­peu­tics. The Lex­ing­ton, MA-based biotech $CNCE is prepar­ing to broad­en its pipeline of deu­teri­um chem­istry prod­uct can­di­dates — a pipeline where four out of five pro­grams are cur­rent­ly part­nered — and Beck­er will be very much in­volved in that, ac­cord­ing to a state­ment.

→ Paris-based Ac­ti­cor Biotech has tapped Yan­nick Plé­tan as its first chief med­ical of­fi­cer. A spin­off from the French Na­tion­al In­sti­tute of Health and Med­ical Re­search, the 4-year-old com­pa­ny is de­vel­op­ing an an­tithrom­bot­ic agent for the acute phase of is­chemic stroke. Plé­tan’s clin­i­cal and med­ical ex­pe­ri­ence at Roche and Pfiz­er will be im­por­tant as Ac­ti­cor nav­i­gates the next tri­al phase for its lead can­di­date ACT017.

Ra­jesh Shrotriya, the 15-year chair­man and CEO of Spec­trum Phar­ma­ceu­ti­cals, has been fired, the com­pa­ny an­nounced Sun­day. The ter­mi­na­tion trig­gered a chain of lead­er­ship changes: cur­rent pres­i­dent and COO Joseph Tur­geon is now pres­i­dent and CEO, as well as a board of di­rec­tor mem­ber; di­rec­tor Stu­art Krass­ner fills the chair­man seat; and Thomas Riga (EVP, CCO and head of busi­ness de­vel­op­ment) be­comes COO. Tur­geon is an Am­gen vet who used to over­see com­mer­cial ac­tiv­i­ties for Spec­trum.

→ For­est Labs vet Charles Ryan will take the CEO’s job at Neu­rotrope $NTRP fol­low­ing the res­ig­na­tion of Su­sanne Wilke.

→ In line with CEO George Scan­gos’ vi­sion for Vir Biotech­nol­o­gy to be a sci­ence-dri­ven com­pa­ny, im­mu­nol­o­gist An­to­nio Lan­za­vec­chia has been brought on as SVP and se­nior re­search fel­low. His main charge is to pro­vide sci­en­tif­ic lead­er­ship for Vir’s tech­ni­cal pro­grams look­ing in­to se­ri­ous in­fec­tious dis­eases. While do­ing that for the San Fran­cis­co up­start, he will con­tin­ue his roles as di­rec­tor of the In­sti­tute for Re­search in Bio­med­i­cine in Bellinzona, Switzer­land and as pro­fes­sor at the Uni­ver­sità del­la Svizzera ital­iana.

→ Fol­low­ing No­vem­ber’s IPO, Apel­lis Phar­ma­ceu­ti­cals $APLS has ap­point­ed Tim­o­thy Sul­li­van, for­mer­ly a VC firm part­ner, as CFO. Sul­li­van has spent the past three years as an ob­serv­er on Apel­lis’ board of di­rec­tors, as the Ken­tucky biotech took its Soliris ri­val drug and age-re­lat­ed mac­u­lar de­gen­er­a­tion ther­a­py fur­ther along the pipeline, rais­ing mon­ey even af­ter a foiled first IPO at­tempt. Now Apel­lis is ready to en­ter Phase III tri­als for both pro­grams in 2018, and in his new role, Sul­li­van will lead the de­vel­op­ment of its fi­nanc­ing and growth strat­e­gy.

→ Long­time EVP and CFO Ryan May­nard is re­sign­ing from South San Fran­cis­co-based Rigel Phar­ma­ceu­ti­cals $RIGL for undis­closed rea­sons (but cer­tain­ly not due to a dis­pute or dis­agree­ment with the com­pa­ny, ac­cord­ing the to SEC fil­ing). Nel­son Ca­bat­u­an, cur­rent VP of fi­nance, will step in as the in­ter­im prin­ci­pal ac­count­ing of­fi­cer while the biotech search­es for a re­place­ment ahead of its lead drug’s PDU­FA date.

Bellerophon Ther­a­peu­tics $BLPH has qui­et­ly hired a new CFO, As­saf Ko­rner, to re­place Megan Schoeps, who re­signed a cou­ple weeks ago. Ko­rner has worked a slate of fi­nan­cial jobs at med­ical de­vice and con­sumer prod­uct com­pa­nies such as Syneron Med­ical, Ilu­mi­nage Beau­ty and KP­MG.

→ Af­ter wow­ing in­vestors with its BC­MA-tar­get­ing CAR-T at ASH, blue­bird bio $BLUE turned to its in­ter­nal op­er­a­tions and named Ko­ry Went­worth VP of fi­nance and prin­ci­pal ac­count­ing of­fi­cer. A vet­er­an of big pub­lic ac­count­ing firms, Went­worth cut his teeth in biotech con­troller­ship dur­ing his 9-year run at Alex­ion. He fills the shoes of Jef­frey Walsh, the biotech’s chief fi­nan­cial and strat­e­gy of­fi­cer, who will con­tin­ue to serve in the prin­ci­pal fi­nan­cial role.

→ British dis­cov­ery and de­vel­op­ment ser­vice provider Con­cept Life Sci­ences has hired An­drew Scott as head of bioas­say de­vel­op­ment and screen­ing, and Ma­g­a­lie Fer­bach as busi­ness de­vel­op­ment di­rec­tor for South­ern and Cen­tral Eu­rope. Scott has ex­pe­ri­ence span­ning phar­ma, biotech and CRO, while Fer­bach’s back­ground is in agro­chem­i­cals. These ap­point­ments wrap up Con­cept’s ex­pand­ing year, marked by the ac­qui­si­tion of Aquila Bio­med­ical in Ed­in­burgh and open­ing of new lab­o­ra­to­ry space at Alder­ly Park.

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.